Exact Amount™The mg quantity of material provided in the smallest pack size for this product is specified on the vial label to two decimal places. This reduces concentration variation and ensures reproducibility in your experiments.
LDN193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3. BMPs induce Smad1/5/8 plus non-Smad pathways, such as MAPK and Akt. BMP signaling pathway is the key regulator of cell fate decisions during embryogenesis and tissue homeostasis. It inhibits the activation of p38, ERK1/2 and Akt in C2C12 cells. LDN193189 only weakly inhibits ALK4, ALK5, and ALK7. LDN193189 affects not only the Smad but also the non-Smad signalling pathways induced by either BMP2, BMP6 or GDF5.
LDN193189 inhibits ectopic ossification and it is a potential agent in the treatment of NSCLC lung tumors, showing significant in-vivo clinical utility. LDN193189 has been used to reduce ectopic ossification in a mouse model of Fibrodysplasia ossificans progressiva.
LDN-193189, LDN 193189
1. Yu, PB., et al. 2008. Nat Med. 14(12): 1363-1369. PMID: 19029982
2. Yu, PB., et al. 2008. Nat Chem Biol. 4(1): 33-41. PMID: 18026094 3. Cuny, GD. 2008. Bioorg Med Chem Lett. 18(15): 4388-4392. PMID: 18621530
4. Heisenberg, CP. and Solnica-Krezel, L. 2008. Curr Opin Genet Dev. 18(4): 311-316. PMID: 18721878